Cardior Pharmaceuticals is a clinical stage biopharmaceutical company founded in 2016 as spin-off from Medical School Hannover (MHH). 
The company is focused on the discovery, development and clinical validation of noncoding RNA therapeutics as innovative medicines for cardiovascular disease patients with various forms of cardiomyopathy and heart failure.

 

LATEST NEWS:

Cardior at 21st Bio€quity Europe
Cardior team will attend and present at Bio€quity Europe, from 17th to 19th May.

For further details please see our news section.

  

 

 

 

Tackling the roots of
Cardiovascular Diseases

Cardiovascular disease is the major contributor to the healthcare burden and mortality worldwide. Based on a number of platform technologies in target discovery and validation together with our worldwide leading competence in noncoding RNA biology, Cardior has developed a rich pipeline of targets involved in various forms of cardiomyopathies and heart failure. This includes general ischemic and non-ischemic driven heart failure, as well as dilated and hypertrophic cardiomyopathies. Our approach provides a novel class of therapeutics and diagnostics to combat cardiac  diseases with high unmet medical need.

Management Team

CEO & CO-FOUNDER
CLAUDIA ULBRICH, MD
open
close
CEO & CO-FOUNDER
CLAUDIA ULBRICH, MD

Dr. Claudia Ulbrich is an MD and health economist (ebs) by training with more than 25 years of expertise in the health care industry including managerial experience in stock listed biotech companies. She brings a broad range of experience in management and consulting and a strong network in venture capital, academia and industry, health economy, political and trade associations.
 
Claudia combines a high level of commercial competence (deal volume up to €2bn) with a sound knowledge of medical affairs and drug development along the valuation chain. With her proven ability in financing, deal closing and deep experience in strategy she is responsible for corporate development and investor relations.
 
Claudia is an integrative, experienced leader with proven success guiding international, cross functional teams. Claudia has worked in the pharmaceutical industry before she founded her first biotech company in 1998 (IPO 2006). She served as Cofounder and interim manager of several international biotech companies. Three years at PricewaterhouseCoopers as a Senior Advisor in Life Sciences were the backbone at the start of her own consulting business in 2008 .

CSO & Founder
PROF THOMAS THUM, MD, PhD
open
close
CSO & Founder
PROF THOMAS THUM, MD, PhD

Prof. Dr. Dr. med Thomas Thum is since 2009 the Director of the Institute of Molecular and Translational Therapeutic Strategies (IMTTS) at Hannover Medical School (MHH), since 2013 visiting Professor at the National Heart and Lung Institute at Imperial College London and since 2021 Director of  the neighboring Fraunhofer Institute for Toxicology and Experimental Medicine (ITEM) in Hannover, Germany.
 
Thomas is a key opinion leader in heart failure and the development of RNA-based therapeutic strategies in cardiovascular medicine. He authored of over 400 scientific publications, appearing in leading journals e.g. Nature  or Lancet.
 
Thomas is also a member of the editorial boards of the world’s most prestigious journals for cardiovascular research. Furthermore, Thomas is a nucleus member of national and international research committees in the cardiovascular field, such as the European Society of Cardiology (ESC), the American Heart Association (AHA), and the International Society for Heart Research (ISHR). Thomas has received numerous awards for his work on non-coding RNAs in cardiovascular research. Thomas has filed over 40 patents, nine of which have been successfully licensed to pharma companies and are currently at phase I/II clinical development. Thomas is founder and CSO of Cardior.

CMO
WILFRIED HAUKE, MD
open
close
CMO
WILFRIED HAUKE, MD

Dr. Wilfried Hauke is a physician by training specialized in pharmaceutical medicine. With more than 30 years working in various fields of the pharmaceutical industry he gained outstanding experience in designing and leading clinical research studies, drug development and regulatory strategies. Wilfried exhibits a wide range of competences in management and consulting starting his career at Hoechst AG, Frankfurt and Roussel UCLAF, Paris where he was involved in the clinical development of antibiotics and cardiovascular drugs. More recently Wilfried took over responsibility as CMO for Trophos, Marseille and was key in medical matters of their assets, which were successfully acquired by Roche in 2015. As CMO and board member of a stock listed company, Wilfried adapted the lead compound development strategy and initiated change management processes. Throughout his career he successfully set focus in risk-benefit-analysis and completed due diligence projects supporting seller and purchaser perspective. He serves as Qualified Person for Pharmacovigilance for UK based pharma companies and supports as Medical Advisor orphan drug developments. Wilfried built up a strong network of research specialists as well as high ranking industrial partners and investors. Wilfried joined Cardior as CMO in early 2018.

Board

MARKUS HOSANG, PhD
open
close
MARKUS HOSANG, PhD

Markus is a General Partner and Managing Director at BioMedPartners in Basel, a  venture capital firm that manages the BioMedInvest family of funds. He obtained his PhD in Biochemistry from the ETH in Zurich and pursued his postgraduate training at Stanford University Medical School in neurobiology and subsequently at the University of Washington Medical School in Seattle.

He is currently on the board of directors of AlevaNeurotherapeutics, Anergis, Hookipa Biotech and Imevax, and was on the board of directors of SuppreMol, Okairos, GenKyoTex, Avontec and Neuraxo Pharmaceuticals. Prior to joining BioMedPartners, Markus was a venture partner at MPM Capital, where he managed their European office in Munich, was co-responsible for their European deal flow and served on the boards of several of their European portfolio companies including Omrix Pharmaceuticals, Kourion, IDEA and Atugen.

Before that Markus was at Roche in Basel for nearly 20 years, where he held several senior management positions of increasing importance in the Pharma R&D organisation. Among these were director and vice president of the global Pharma R&D strategy unit and a member of the board of Pharma R&D Directors for many years. In this virtue he was directly involved in several major strategic transactions of Roche.

Markus served on the board of directors and the board of trustees of the Swiss Foundation for Stipends in Medicine and Biology (SSMBS) as its treasurer during 1994-2002, and is currently the vice chairman of the board of directors of Unitectra AG, the combined technology transfer office of the universities of Zurich, Bern and Basel.  Markus has published numerous articles in peer-reviewed journals and holds several patents.

KARIN KLEINHANS, PhD
open
close
KARIN KLEINHANS, PhD

Karin Kleinhans, PhD joined LSP in 2015 as an associate and became an Investment Manager in 2019. Karin provides in-depth analytical support to the LSP investment team at all stages of the investment process. She is involved in a number of LSP corporate projects as well.
Prior to joining LSP, Karin was an associate in an international patent law firm where she was involved in all aspects of the patent life cycle for international clients from the biotech industry. Previously, she gained experience in clinical trials and regulatory affairs within pharmaceutical drug development. Before, Karin was a researcher at the Max-Planck Department for Stem Cell Aging and the Institute of Molecular Medicine at the University Ulm. Her research focused on the basic mechanisms of cellular and organismal aging, specifically on stem cell aging. In particular, she focused her research on the impact of DNA damage and repair on stem cell aging and regeneration. Karin participated as a speaker in scientific meetings and lead scientific collaborations with world leading experts in the stem cell and aging field. She authored a number of scientific publications and book chapters in renowned journals. Karin received her PhD from the International Graduate School in Molecular Medicine in Ulm funded by the Excellence Initiative of the German Federal and States Governments. She was awarded her Bachelor`s and Master`s Degree in Molecular Medicine where she combined medical studies with scientific research training.

ULRICH GRANZER, PhD
open
close
ULRICH GRANZER, PhD

Ulrich is the founder and owner of Granzer Regulatory Consuting & Services and has more than 25 years of experience in drug development and regulatory affairs. He has held senior management positions at Glaxo as Director of Regulatory Affairs and was a member of Glaxo Wellcome's Global Regulatory Board.

Ulrich has broad experience in drug development including oligonucleotides. At BASF Pharma he served as Vice President of Global Regulatory Centres, assuming global responsibility for Regulatory Affairs, Drug Safety, and GXP in drug development. At Knoll he was responsible for the development of small molecules as well as several biological compounds in the indications of obesity, stroke, septic shock, and rheumatoid arthritis.

He was instrumental to the program for the first fully human anti TNF antibody, now marketed as Humira. Before starting his own consultancy in 2002, he joined Bayer as Vice President of Global Regulatory Affairs, whose responsibility extended over all regulatory aspects of development and submission projects worldwide."

FRANK KALKBRENNER, PhD
open
close
FRANK KALKBRENNER, PhD

Frank is the Global Head of the Boehringer Ingelheim Venture Fund. He served as board member of STAT Diagnostica (acquired by Qiagen in 2018), Hookipa Biotech (IPO at NASDAQ in 2019) and Amal Therapeutics (acquired by Boehringer Ingelheim in 2019). Currently, he is on the Boards of Cardior Pharmaceuticals, eTheRNA, Aelin Therapeutics, RinRi Therapeutics, Acousia Therapeutics, T3 Pharma, T-Knife and Brainomix. 
Frank is a physician by training did his PhD in Pharmacology and specialized in Pharmacology and Toxicology. He spent more than 10 years in academic research in the Max-Planck-Institute for Molecular Genetics in Berlin and in the Institute of Pharmacology of the Freie Universität, Berlin.
He began his industrial career at Schering AG and moved in 1999 to Boehringer Ingelheim joining Pulmonary Research. In 2005, he took over the responsibility for the Licensing Department. In this function, he was responsible for the licensing activities of the German Boehringer Ingelheim organization in various indication areas. In addition, he built up the Biological Research unit at the German Research site in Biberach. 
In 2010 - shortly after its initiation - Frank joined the Boehringer Ingelheim Venture Fund.

MARTIN CROOK, PhD
open
close
MARTIN CROOK, PhD

Martin serves as Global Lead Cardiovascular & Translational Medicine, Search & Evaluation, Business Development at Bristol-Myers Squibb. He leads global scouting and diligence activities for therapeutic opportunities in cardiovascular disease and pharmacodiagnostics across therapeutic areas including immuno-oncology. 

Previous to joining BMS, from 2005-2012 Martin led drug discovery teams at Merck Research Laboratories to discover and develop novel pharmaceutical therapies for the treatment of cardiovascular disease. In 2012, Martin joined Daiichi Sankyo to find business development opportunities in cardiometabolic disease and subsequently joined Bristol-Myers Squibb Business Development in 2015.

Martin received his B.Sc. Hons. from Lancaster University in 1995, a MSc in Immunology and Oncology from University of Birmingham in 1996 and his Ph.D., in cardiovascular disease, from the University of Bristol in 2000. Martin then went on to receive his postdoctoral training in Dr Elizabeth Nabel's Vascular Biology Branch of the National Heart Lung and Blood Institute (NIH) in Bethesda, Maryland.

PROF JOHANN BAUERSACHS, MD
open
close
PROF JOHANN BAUERSACHS, MD

Professor Bauersachs acts as Head of the Department of Cardiology at Hannover Medical School (MHH). He studied Medicine at the University of Freiburg. After training as Clinical and Research Fellow at the Universities of Frankfurt and Heidelberg/Mannheim, in 1999 he moved to the University Hospital Wuerzburg where he became Consultant and Lecturer in Internal Medicine and Cardiology and was Associate Professor in the Department of Medicine from 2008 to 2010. Since 2010 Johann has been a full professor and director of the Department of Cardiology and Angiology at Hannover Medical School. 

Professor Bauersachs is Fellow and Board Member of the Heart Failure Association (HFA) of the ESC, Chair of the HFA Study Group on Peripartum Cardiomyopathy, and Past Chair of the Working Group on Myocardial Function. He is Chair of the Cardiovascular Section of the Fachkollegium Medizin,  Deutsche Forschungsgemeinschaft (DFG), Member of the Steering Committee of the DFG-funded  Cluster of Excellence REBIRTH, and Speaker of the Clinical Research Group (KFO) 311 “(Pre-)terminal heart and lung failure - mechanical unloading and repair” funded by the DFG. 

Professor Bauersachs is an interventional cardiologist with special interests in acute coronary syndromes, left ventricular healing and remodelling, acute and chronic heart failure, as well as intensive care. He is particularly interested in the pathophysiology and treatment of peripartum cardiomyopathy, in aldosterone and mineralocorticoid receptor-mediated mechanisms, and in the role of non-coding RNAs. He is Study Chair of the DIGIT-HF study investigating the effect of Digitoxin on morbidity/mortality in patients with advanced heart failure, and is extensively involved in many other clinical trials. He has indicated his willingness to serve as an advisor for clinical strategy

Scientific Advisory Board

ARTHUR A. LEVIN, PhD
open
close
ARTHUR A. LEVIN, PhD

Arthur A. Levin, Ph.D. is Avidity Bioscience’s Executive Vice President of Research and Development. Dr. Levin has nearly 20 years of experience in the research and development of RNA-targeting therapeutics and 30 years of experience in the pharmaceutical industry. He has been involved in the development of more than 20 oligonucleotide therapeutics in clinical trials including both approved antisense drugs.

Prior to joining Avidity Dr. Levin ran Research and Development at miRagen Therapeutics and was Chief Development Officer at Santaris Pharma (Copenhagen) where he led the efforts on the first microRNA targeting therapeutic currently in Phase 2 clinical trials.  Before joining Santaris Pharma, Dr. Levin consulted for leading biotechnology and pharmaceutical companies, conducting research and development in RNA-based therapies such as mRNA, microRNA, and siRNA.

Prior to consulting, Dr. Levin was Senior Vice President of Development at Isis Pharmaceuticals, where he was responsible for the drug development of Isis’ products across a range of therapeutic areas. His expertise was instrumental in advancing more than a dozen oligonucleotide drugs from basic research to clinical development in areas such as neuromuscular diseases, infectious diseases, metabolic disorders, cardiovascular disease and cancer.

He joined Isis from Hoffmann-La Roche Inc. where he was Research Leader and made fundamental discoveries in retinoid therapeutics.  Dr. Levin holds a Ph.D. in Toxicology from the University of Rochester School of Medicine and Dentistry, New York and a B.S. in Biology from Muhlenberg College. He completed his post-doctoral work at the Chemical Industry Institute of Toxicology in Research Triangle, North Carolina. He the author of more than 70 papers and book chapters.

DAVID CRANDALL, PhD
open
close
DAVID CRANDALL, PhD

David Crandall brings both scientific and executive R&D leadership experience from 30 years in the pharmaceutical industry.  Before joining the Scientific Advisory Board of Cardior Pharmaceuticals, Dr. Crandall held a leadership position at Johnson & Johnson, where he was responsible for the executive management of the heart failure portfolio, which included both small molecule and biopharma programs from preclinical discovery through early clinical development. 

He was instrumental in developing a hybrid research model blending internal expertise with external opportunities from academia and biotech to successfully advance programs into early clinical development.  As a component of this position, Dr. Crandall was a key corporate representative in discussions with potential partners and equity analysts.  Prior to joining Johnson & Johnson, Dr. Crandall held positions of increasing responsibility in pharmaceutical R&D at Bristol-Myers Squibb and Wyeth (Pfizer) Research. 

Dr. Crandall received his Ph.D. in Physiology from Iowa State University and was an NIH postdoctoral fellow in Endocrinology/Medicine at Emory University.  He is the author of numerous peer-reviewed scientific publications, book chapters and U.S. and foreign patents, and has served on the editorial boards of key journals in the field of drug discovery.

PROF DOUGLAS L. MANN, MD
open
close
PROF DOUGLAS L. MANN, MD

Dr. Mann is the Lewin Chair and Professor of Medicine, Cell Biology and Physiology, Chief of the Division of Cardiology at the Washington University School of Medicine, and Cardiologist in Chief at Barnes Jewish Hospital in St. Louis. He received his medical degree from Temple University School of Medicine in Philadelphia and completed fellowships in clinical cardiology at the University of California San Diego, and Massachusetts General Hospital in Boston.

Dr. Mann's primary research interest has been the molecular and cellular basis of heart failure, with particular emphasis on the role of innate immunity in disease progression and recovery of the failing heart. The author of numerous peer reviewed articles on the role on inflammatory mediators in cardiac remodeling and myocardial recovery, Dr. Mann is also the editor of Heart Failure, A Companion to Braunwald’s Heart Disease, and a co-editor of Braunwald’s Heart Disease, the leading textbook in cardiovascular medicine. 

Dr. Mann is the founding editor for JACC: Basic to Translational Science, and is currently the on the Editorial Board for a number of leading cardiovascular journals. He is a member of the American Society for Clinical Investigation, the Association of American Physicians the Association of University Cardiologists, the Heart Failure Society of America and the American Clinical and Climatological Association. He is the past president of the Heart Failure Society. 

PROF FAIEZ ZANNAD, MD, PhD
open
close
PROF FAIEZ ZANNAD, MD, PhD

Faiez Zannad, MD, PhD, FESC is Professor of Therapeutics at the University of Lorraine in Nancy, France. Cardiologist and heart failure specialist, PhD in clinical pharmacology (Oxford, UK). Head of the Division of Heart Failure and Hypertension and Director of the Inserm Clinical Investigation Center at “Institut Lorrain du Coeur et des Vaisseaux”, Nancy. 

Professor Zannad leads two EU FP7 granted programs: HOMAGE (omics biomarkers for mechanistic phenotyping and prediction of drug response) and FIBROTARGETS (fibrosis as a biotarget).

As the primary investigator or member of oversight committees in major clinical trials, he pioneered and/or made significant contributions to evidence-based heart failure therapy, mainly mineralocorticoid receptor antagonists (RALES, EPHESUS, EMPHASIS-HF), and beta-blockers (CIBIS) as well as in major comorbid diseases such as sleep disordered breathing (SERVE-HF), autonomic nervous dysfunction (NECTAR-HF, BEAT-HF), and diabetes (EXAMINE, EMPEROR), chronic kidney disease (FOSIDIAL, AURORA, ALCHEMIST), in diabetes (EXAMINE, EMPEROR), thrombosis in heart failure (COMMANDER-HF).

He served as Chairman of the French Society of Hypertension, Chairman of the ESC Working Group on pharmacology and drug therapy, and board member of the ESC Heart Failure Association. He is the founder and is currently organizing the Global CardioVascular Clinical Trialists (CVCT) Forum and Workshop, an annual international think tank gathering dedicated to the science of clinical trials, with meetings in Paris, Washington DC, Middle East and Asia.

As of 2016 Prof Zannad published more than 600 peer-reviewed papers. In 2014, he was awarded the European Society of Hypertension Paul Milliez Award and in 2017 the Lifetime Achievement Award from the ESC Heart Failure Association.

PROF SCOTT SOLOMON, MD
open
close
PROF SCOTT SOLOMON, MD

Scott D. Solomon, MD is The Edward D. Frohlich Distinguished Chair, Professor of Medicine at Harvard Medical School, Director of Noninvasive Cardiology and Senior Physician at Brigham and Women’s Hospital. He directs the Cardiac Imaging Core Laboratory and the Clinical Trials Endpoints Center at Brigham and Women’s Hospital.

He received his A.B. from Williams College and his M.D. from Harvard Medical School. Dr. Solomon’s research interests have focused on changes in ventricular structure and function following myocardial injury, modifiers of risk and influences of outcome in patients following myocardial infarction and with chronic heart failure, cardiovascular safety of non-cardiovascular therapies, factors that influence the transition from hypertension to heart failure, and heart failure with preserved ejection fraction.

He has pioneered the use of cardiac imaging in cardiovascular drug and device development and use of imaging in clinical trials. He and his research group have played a leading role in many international clinical trials in heart failure, hypertension and myocardial infarction.

He led the NIH sponsored Celecoxib Cross-trials Safety Study which directly informed regulatory agencies about the safety of widely used non-steroidal anti-inflammatory agents. He directs the Cardiac Imaging Center for the NHLBI Atherosclerosis Risk in Communities (ARIC) study and Hispanic Community Health Study – Study of Latinos (HCHS-SOL), the two largest NIH cohort studies.

Dr. Solomon has recently studied the role for angiotensin receptor neprilysin inhibition in heart failure. Dr. Solomon leads a research group consisting of 10 faculty members, 8 research fellows and 40 support staff. He has directed the Harvard Medical School Cardiovascular Clerkship and the Echocardiography training program at Brigham and Women’s Hospital.

He has authored more than 400 peer-reviewed articles, reviews and editorials, two textbooks of cardiac imaging.. He is listed by Thomson-Reuters as one of the most highly cited scientists in the past 10 years. He is a Cardiology Section Editor at UpToDate and Internatonal Associate Editor at the European Heart Journal.

PROF JAVED BUTLER, MD
open
close
PROF JAVED BUTLER, MD

Javed Butler, is the Patrick H. Lehan Chair in Cardiovascular Research, and Professor and Chairman of the Department of Medicine at the University of Mississippi Medical Center. He is also Professor of Physiology. Prior to joining the University of Mississippi, he was Charles A. Gargano Professor and Director of the Division of Cardiovascular Medicine and Co-Director of the Heart Institute at Stony Brook University, New York. He had served as the director for heart failure research at Emory University and director of the heart and heart-lung transplant programs at Vanderbilt University prior to that.
He received his medical degree from the Aga Khan University and completed residency training at Yale University, cardiology fellowship and advanced heart failure and transplant fellowships at Vanderbilt University, and cardiac imaging fellowship at the Massachusetts General Hospital at the Harvard Medical School. He has completed Master of Public Health degree from Harvard University and Master in Business Administration from Emory University.
Dr. Butler's research interests focus on clinical trials in patients with heart failure. He serves on several national committees for the American College of Cardiology, American Heart Association, National Institutes of Health, and the Heart Failure Society of America. He is the recipient of the Simon Dack Award by the American College of Cardiology as well as the Time, Feeling, and Focus Award by the American Heart Association.
Dr. Butler has authored more than 550 peer-reviewed publications. He serves on the editorial board of several peer reviewed cardiovascular journals. He has been cited numerous times in America’s Best Doctors list.
 

Technology

Noncoding RNA therapeutics

Noncoding ribonucleic acids (ncRNAs) such as microRNAs and long noncoding RNAs (lncRNAs) are endogenous molecules that act as regulators of cellular functions. Their aberrant regulation contributes to the development of many diseases including cardiovascular diseases. Blocking ncRNAs with synthetic antisense oligonucleotides or substituting these molecules by synthetic RNAs allows a normalisation of cellular function. Cardior’s research and discovery approaches provide a novel class of therapeutics with unique and revolutionary mode of action by modulating entire disease pathways at the cellular level, thereby enabling the treatment of diseases with high unmet medical need.

Cardior’s core innovation, the patented and proprietary compound CDR132L is an oligonucleotide-based ncRNA inhibitor, directed against the microRNA miR-132, halting and reversing the development of cardiac remodelling. CDR132L has several distinguishing features:

 

UNIQUE MoA

DELIVERY

CDR132L is a highly stable water-soluble oligonucleotide and formulated for parenteral or subcutaneous application.

APPLICATION

The current treatment stipulates monthly dosing.

EVIDENCE

Non-clinical efficacy demonstrated in several HF indications in human-relevant HF model in pigs, as well as in human cardiac tissues and cells.  Foinquinos et al. 2020    Batkai et al. 2020
Clinical Phase 1b study in HF patients successfully completed showing no safety signals and beneficial treatment effects. [Täubel et al. 2020]

Wholly-owned ncRNA platform targeting Cardiovascular Diseases(CVDs) - Therapy pipeline

nc=non-coding

News

Cardior at 21st Bio€quity Europe
Cardior team will attend and present at Bio€quity Europe, from 17th to 19th May read more

BioEquity Europe 2021 will be held in digital format. BioEquity is the industry’s premier international showcase for financial dealmakers and pharmaceutical executives to assess and network with rising biotechs.

close
Cardior´s CSO Prof. Thomas Thum Receives Prestigious Paul-Martini-Award for His Achievements in Developing Novel, Causative Heart Failure Treatments
Cardior's CSO Prof. Dr. Dr. med. Thomas Thum received the Paul Martini Award for the conception and initial testing of a new form of therapy for cardiac insufficiency - also known as heart failure. The prize is awarded annually by the Paul Martini Foundation, Berlin, for outstanding achievements in clinical therapeutic drug research. read more

For more information please follow the link: https://www.paul-martini-stiftung.de/paul-martini-preis/2021/

(German only)

close
Cardior´s CSO Prof. Thomas Thum Receives Prestigious Paul-Martini-Award for His Achievements in Developing Novel, Causative Heart Failure Treatments
Cardior's CSO Prof. Dr. Dr. med. Thomas Thum received the Paul Martini Award for the conception and initial testing of a new form of therapy for cardiac insufficiency - also known as heart failure. The prize is awarded annually by the Paul Martini Foundation, Berlin, for outstanding achievements in clinical therapeutic drug research. read more

For more information please follow the link: https://www.paul-martini-stiftung.de/paul-martini-preis/2021/

(German only)

close
Independent Peer-Reviewed Study Validates Therapeutic Mode of Action of Cardior's First-in-Class Heart Failure Program
Publication of international research group in Frontiers in Cardiovascular Medicine confirms key role of miR-132 in cardiovascular diseases read more

Hanover, Germany, March 29, 2021 - Cardior Pharmaceuticals GmbH, a clinical-stage biotech company focused on the development of non-coding RNA (ncRNA) based therapeutics for patients with cardiovascular diseases, announced today that a recent peer-reviewed study confirms the therapeutic mode of action of Cardior´s lead program CDR132L. CDR132L blocks the naturally occurring microRNA miR-132 which, if overexpressed, is a key driver of heart failure.

Download press release here

close
Cardior's pioneering miRNA approach in heart failure endorsed by expert opinions in the European Heart Journal
- First-ever development of an RNA therapeutic for heart failure
- Successful translation of unique scientific discovery into first-in-class clinical program
read more

Hanover, Germany, February 9, 2021 - Cardior Pharmaceuticals GmbH, a clinical-stage biotech company focused on the development of non-coding RNA (ncRNA) based therapeutics for patients with cardiovascular diseases, announced today that the Phase Ib results as well as preclinical and large-animal data of the Company’s lead compound CDR132L were published alongside with two editorials from independent experts in the European Heart Journal Volume 42, Issue 3, January 14, 2021, an issue focusing on ischemic heart diseases.

You can download the full press release her.

close
Cardior featured in BioCentury
Cardior is featured in the BioCentury issue of January 4, 2021 with the “Emerging Company Profile” read more
First-In-Human Heart Failure Data of Cardior Pharmaceuticals´ Novel miRNA Antisense Therapy Presented at the 17th Global Cardiovascular Clinical Trialists Forum
- Excellent safety and tolerability of first-in-class compound CDR132L
- Novel mode of action confirmed by data on cardiac function and biomarkers read more

Hanover, Germany, December 8, 2020 - Cardior Pharmaceuticals GmbH, a clinical-stage biotech company focused on the development of non-coding RNA (ncRNA) based therapeutics for patients with cardiovascular diseases, today announced that its Chief Scientific Officer Thomas Thum, MD, PhD, has presented clinical data on the Company´s lead compound CDR132L at the 17th Global Cardiovascular Clinical Trialists Forum (CVCT) on December 7, 2020. 
In his talk titled "The promise of novel miRNA antisense therapy in patients with heart failure", he summarized the first-in-human data of Cardior Pharmaceuticals´ novel miRNA compound CDR132L in patients with chronic heart failure. Building on a completely novel mode of action, the compound is an antisense oligonucleotide inhibiting the non-coding microRNA-132 (miR132) that directly regulates adverse cardiac remodeling. Thereby, the compound is supposed to halt or even revert heart failure.
In the Phase Ib trial, CDR132L met all endpoints and showed excellent tolerability and safety at all dose levels during the 120-day study period. No safety signals or unexpected adverse events were observed. Moreover, PK data confirmed strong dose-dependent linearity and specific target engagement. An exploratory analysis of multiple pharmacodynamic parameters, including measurement of NT-proBNP blood levels, showed beneficial effects on top of standard of care. Results were published in the European Heart Journal (doi:10.1093/eurheartj/ehaa898).
“These are the first clinical data of a potential miRNA-based therapy in heart failure,” said Faiez Zannad, MD, PhD, FESC is Professor of Therapeutics at the University of Lorraine in Nancy, France, Scientific Advisor to Cardior Pharmaceuticals and Founder and Chairman of CVCT. “We are excited that the efficacy signals previously observed in large animal models could be translated to a human setting. Provided that future clinical trials confirm these promising results, this approach may be transforming heart failure treatment as it directly addresses the roots of the disease.”
"Our goal is to provide new therapeutic options for heart failure patients by halting or even reversing the disease,” said Thomas Thum, Professor at Hannover Medical School and CSO of Cardior Pharmaceuticals. “The first-in-human data of our lead compound CDR132L are very encouraging and suggest that we have indeed discovered a master switch to control the disease. We are now looking forward to initiating Phase II clinical trials in 2021.”

###

 

About CDR132L

CDR132L is an antisense oligonucleotide developed by Cardior Pharmaceuticals inhibiting the microRNA-132 (miR132), a non-coding microRNA that regulates cardiac hypertrophy and remodeling in cardiomyocytes by targeting well-defined pathways.
miR132 is a regulatory master switch to control cardiac function and a promising, causal therapeutic target in heart failure therapy. Expression of miR132 is increased in various pathological cardiac conditions in both animals and humans, and previous preclinical studies have shown that miR-132 is essential for driving the pathological growth of cardiomyocytes. 
In a randomized, double-blind, placebo-controlled, dose-escalating Phase Ib study, the compound showed excellent safety and tolerability as well as promising pharmacokinetic (PK) and pharmacodynamic (PD) properties in patients with stable heart failure (HF) of ischemic origin (NYHA 1-3). The study design combined dose escalation with repeat dosing (day 1 and 28) at 4 dose levels. 28 patients received CDR132L or placebo (5:2 randomized in 4 cohorts) via short-term (15 min.) intravenous infusions as add-on therapy to standard of care. 
About Cardior
Cardior Pharmaceuticals is a privately held German biopharmaceutical company pioneering the development of curative and preventive heart failure therapeutics based on non-coding RNAs (ncRNAs). Cardior’s therapeutic approach is using distinctive ncRNA signatures driving the molecular reprogramming that causes maladaptive remodeling and heart failure. Drug candidates developed by Cardior represent first-in-class ncRNA therapeutics and diagnostics for patients with myocardial infarction and various forms of heart failure. Founded in 2016 based on the work of cardiologist Prof. Dr. Dr. Thomas Thum of Hannover Medical School, the Company has raised EUR 15 Mio. from international investors LSP, BioMedPartners, Boehringer Ingelheim Venture Fund (BIVF), Bristol-Myers Squibb (BMS) and High-Tech Gründerfonds (HTGF).

 

Contact Cardior

Dr. Claudia Ulbrich / Barbara Gaertner-Rupprecht
Cardior Pharmaceuticals GmbH
Feodor-Lynen-Str. 15
30625 Hanover
Germany
Tel: +49 511 33 85 99 30

 

Media Inquiries
akampion
Dr. Ludger Wess / Ines-Regina Buth 
Managing Partners
info@akampion.com
Tel. +49 40 88 16 59 64
Tel. +49 30 23 63 27 68

close
PRESENTATION AT CVCT FORUM 2020 DECEMBER 7th
PROF. DR. THOMAS THUM, CSO OF CARDIOR PHARMACEUTICALS, PRESENTS AT CVCT FORUM 2020 read more

Thomas Thum will give the lecture "The Promise of Novel miRNA Antisense Therapy in Heart Failure Patients" at the 17th Global Cardio Vascular Clinical Trialists (CVCT) Forum on December 7th from 2:00 pm to 2:10 pm EST within the session “THE FUTURE OF HFrEF TRIALS” (1.30 pm – 3.50 pm EST).

close
Cardior Pharmaceuticals Announces Positive Phase Ib Results of its Lead Compound CDR132L in Heart Failure
First-in-class compound showed excellent tolerability and safety

Unique mode of action in chronic heart failure confirmed by data on cardiac function and biomarkers

Phase II studies in subacute and chronic heart failure planned

read more

Hanover, Germany, November 12, 2020 - Cardior Pharmaceuticals GmbH, a clinical-stage biotech company focused on the development of non-coding RNA (ncRNA) based therapeutics for patients with cardiovascular diseases, announced today positive results of a Phase Ib study with its lead compound CDR132L. The compound is an antisense oligonucleotide inhibiting the non-coding microRNA-132 (miR132) that directly regulates adverse cardiac remodeling. This first-in-human study was performed in cooperation with Richmond Pharmacology Ltd., London, UK (clinicaltrials.gov: NCT04045405). Results were published in the European Heart Journal (doi:10.1093/eurheartj/ehaa898).
In the trial, CDR132L met all endpoints and showed excellent tolerability and safety. The randomized, double-blind, placebo-controlled, dose-escalating study was designed to assess safety, pharmacokinetic (PK) and pharmacodynamic (PD) properties of CDR132L in patients with stable heart failure (HF) of ischemic origin (NYHA 1-3). The study design combined dose escalation with repeat dosing (day 1 and 28) at 4 dose levels. 28 patients received CDR132L or placebo (5:2 randomized in 4 cohorts) via short-term intravenous infusions as add-on therapy to standard of care.
Primary endpoint was safety and tolerability of CDR132L as assessed during the 120-day study period. The characterization of CDR132L’s PK profile in heart failure patients served as secondary endpoint. In addition, the effect of CDR132L on the target miR132 and on certain HF-relevant PD parameters was analyzed in an exploratory manner.
The infusion was very well tolerated by all patients with no injection-related signs. No safety signals or unexpected adverse events were observed for CDR132L. PK data showed strong dose-dependent linearity and specific target engagement could be confirmed. Exploratory analysis of multiple pharmacodynamic parameters, including measurement of NT-proBNP blood levels, showed beneficial effects on top of standard of care and will be used for planning Phase II proof-of-concept studies. 
“CDR132L did not show any signs of toxicity regardless of dose level. As expected, the pharmacokinetic characteristics were found to be dose-dependently linear,” said Dr. Thomas Thum, Professor at Hannover Medical School and CSO of Cardior. “In addition, the target engagement data confirmed the mode of action of CDR132L. We also observed positive changes of various markers which in our preclinical models were strong signs of efficacy. In sum, the analysis of relevant surrogate pharmacodynamic parameters showed promising beneficial results in these patients, even after only two administrations of CDR132L.” 
He added that the observed pharmacodynamic effects of CDR132L are planned to be further investigated in upcoming Phase II studies.
“We are very pleased with the outcome of our clinical study, the first-ever trial of an oligonucleotide-based drug in heart failure patients,” said Claudia Ulbrich, CEO of Cardior. “These encouraging results are an excellent basis for starting Phase II studies in subacute and chronic heart failure patients. The outcome of this trial also underlines the potential of RNA-based therapies as a causal approach to treat complex diseases.”

###

About CDR132L
CDR132L is an antisense oligonucleotide developed by Cardior Pharmaceuticals inhibiting the microRNA-132 (miR132), a non-coding microRNA that regulates cardiac hypertrophy and remodeling in cardiomyocytes by targeting well-defined pathways.
miR132 is a regulatory master switch to control cardiac function and a promising, causal therapeutic target in heart failure therapy. Expression of miR132 is increased in various pathological cardiac conditions in both animals and humans, and previous preclinical studies have shown that miR-132 is essential for driving the pathological growth of cardiomyocytes. 
 

 

About Cardior
Cardior Pharmaceuticals is a privately held German biopharmaceutical company pioneering the development of curative and preventive heart failure therapeutics based on non-coding RNAs (ncRNAs). Cardior’s therapeutic approach is using distinctive ncRNA signatures driving the molecular reprogramming that causes maladaptive remodeling and heart failure. Drug candidates developed by Cardior represent first-in-class ncRNA therapeutics and diagnostics for patients with myocardial infarction and various forms of heart failure. Founded in 2016 based on the work of cardiologist Prof. Dr. Dr. Thomas Thum of Hannover Medical School, the Company has raised EUR 15 Mio. from international investors LSP, BioMedPartners, Boehringer Ingelheim Venture Fund (BIVF), Bristol-Myers Squibb (BMS) and High-Tech Gründerfonds (HTGF).

 

 

 

Contact Cardior
Dr. Claudia Ulbrich / Barbara Gaertner-Rupprecht
Cardior Pharmaceuticals GmbH
Feodor-Lynen-Str. 15
30625 Hanover
Germany
Tel: +49 511 33 85 99 30

 

 

Media Inquiries
akampion
Dr. Ludger Wess / Ines-Regina Buth 
Managing Partners
info@akampion.com
Tel. +49 40 88 16 59 64
Tel. +49 30 23 63 27 68

close
CDR132L: another brick in the wall towards the use of miRNAs to treat cardiovascular disease
Article published by Yvan Devaux and Lina Badimon ...

read more

...in the European Heart Journal, ehaa870, https://doi.org/10.1093/eurheartj/ehaa870, on November 4

This editorial refers to “CDR132L improves systolic and diastolic function in a large animal model of chronic heart failure”, by S. Batkai et al., European Heart Journal, ehaa791, https://doi.org/10.1093/eurheartj/ehaa791

close
Cardior Pharmaceuticals´ Lead Compound Demonstrates Improvement of Heart Function in Chronic Heart Failure Model
- Safety and efficacy of CDR132L established in an in vivo model of chronic post-MI heart failure
- Study by international research team published in European Heart Journal
- Broad treatment potential for chronic heart failure
read more

Hanover, Germany, October 22, 2020 - Cardior Pharmaceuticals GmbH, a clinical-stage biotech company, focused on the development of noncoding RNA (ncRNA) therapeutics for patients with cardiovascular diseases, today announced a publication in the European Heart Journal (doi:10.1093/eurheartj/ehaa791) demonstrating that repeated treatment with its lead compound CDR132L is safe, improves cardiac function and reduces both ventricular as well as left atrial volumes in chronic heart failure. The results were obtained in a clinically relevant, post-myocardial infarction large animal model. The research was conducted by an international team of scientists from Austria, Germany, and Hungary.
 
CDR132L is a synthetic, lead-optimized antisense oligonucleotide inhibiting the microRNA 132 (miR132), a non-coding microRNA that regulates cardiac hypertrophy and autophagy in cardiomyocytes by targeting well-defined pathways. miR132 expression is increased in various pathological cardiac conditions in animals and humans and is both necessary and sufficient to drive the pathological growth of cardiomyocytes. It therefore is regarded as a regulatory master switch that controls cardiac function. Already, Cardior has shown in various in vivo models that inhibition of miR132 is effective in reversing severe heart failure.
 
The results demonstrate that repeated dosing of CDR132L is safe and adequate to provide clinically relevant exposure and therapeutic efficacy by improving both systolic and diastolic cardiac function in this model. CDR132L treatment was started one month after myocardial infarction and the compound was administered as a monthly intravenous injection either five or three times. Cardiac function was assessed in a serial fashion and at the 6 months post-MI endpoint using various clinically relevant methods, among others, cardiac magnetic resonance imaging (cMRI), intracardiac hemodynamic measurements as well as various additional biochemical and histological methods at tissue level.
 
No drug-related adverse events or changes in haematology or laboratory chemistry were observed in the chronic setting, further supporting the previously demonstrated favorable safety profile of the drug.
 
Therefore, based on the available evidence, a CDR132L treatment regime with monthly injections justifies the clinical development in various chronic heart failure settings. The simultaneous improvement of both systolic and diastolic cardiac functions suggests a broad applicability of the compound in chronic heart failure patients in general. 
“This study adds to our growing body of evidence that our lead compound CDR132L is, above all, a safe, efficacious, and novel causal treatment for heart failure, a condition that currently can only be treated symptomatically,” said Dr. Thomas Thum, Professor at Hannover Medical School, CSO of Cardior and corresponding author of the study. “Already, we demonstrated a favorable non-clinical safety profile in a large GLP safety toxicology program in two species, which was a prerequisite for our completed Phase Ib clinical trial in patients with stable chronic heart failure.”
 
“It’s a big step forward to see that CDR132L not only halts and reverses heart failure in this important animal model, but is also safe when administered repeatedly,” said Claudia Ulbrich, CEO of Cardior. "This not only underlines the potential of our approach for treating a broad range of chronic heart failure indications, but also provides hope for many other conditions where a causal treatment is still missing. It’s good news for the entire RNA-based medicine sector.”
 
She added that Cardior is expecting results from its Phase Ib clinical study shortly.
 
###
 
About Cardior
Cardior Pharmaceuticals is a privately held German biopharmaceutical company pioneering the development of curative and preventive heart failure therapeutics based on non-coding RNA (ncRNA). Cardior’s therapeutic approach is using distinctive ncRNA signatures driving the molecular reprogramming that causes maladaptive remodeling and heart failure. Drug candidates developed by Cardior represent first-in-class ncRNA therapeutics and diagnostics for patients with myocardial infarction and heart failure. Founded in 2016 based on the work of cardiologist Prof. Dr. Dr. Thomas Thum of Hannover Medical School, the Company has raised EUR 15 Mio. from international investors LSP Life Sciences Partners, BioMedPartners, Boehringer Ingelheim Venture Fund (BIVF), Bristol-Myers Squibb (BMS) and High-Tech Gründerfonds (HTGF).
 
Contact Cardior
Dr. Claudia Ulbrich / Barbara Gaertner-Rupprecht
Cardior Pharmaceuticals GmbH
Feodor-Lynen-Str. 15
30625 Hanover
Germany
Tel: +49 511 33 85 99 30
 
Media Inquiries
akampion
Dr. Ludger Wess / Ines-Regina Buth
Managing Partners
info@akampion.com
Tel. +49 40 88 16 59 64
Tel. +49 30 23 63 27 68

close
Cardior Pharmaceuticals Demonstrates Reversal of Cardiac Hypertrophy by H19 Gene Therapy
- Administration of AAV9 expressing H19 attenuates cardiac hypertrophy in vivo and prevents progression to heart failure
- Details on novel mechanism of action published in peer-reviewed study in the European Heart Journal read more

Hanover, Germany, July 13, 2020 - Cardior Pharmaceuticals GmbH, a clinical-stage biotech company focused on the development of noncoding RNA (ncRNA) therapeutics for patients with cardiovascular diseases, today announced the results of extensive in vitro and in vivo studies demonstrating the therapeutic potential of H19 gene therapy to combat cardiac hypertrophy and heart failure. Results were published in the European Heart Journal (doi: 10.1093/eurheartj/ehaa519) [1]. Research was performed by an international team of researchers from Germany, Austria, and the U.S.

H19 is an IP-protected target describing a long noncoding RNA (lncRNA) that is transcribed from a highly species-conserved gene locus. H19 expression is downregulated in failing hearts of mice, pigs and humans. To test the idea that H19 might have cardiomyocyte-specific protective functions and therefore may be used as a therapeutic target, the researchers explored a cardiomyocyte-directed gene therapy using an AAV9 vector delivering the murine or the human H19 gene. Gene delivery was not only safe and well tolerated but expression of the H19 lncRNA also led to significantly attenuated heart failure even when cardiac hypertrophy was already established.

The researchers also identified a link between H19 and pro-hypertrophic nuclear factor of activated T cells (NFAT) signaling, further strengthening the hypothesis that the suppression of this long non-coding RNA plays a crucial role in the development of heart failure.
“We were able to demonstrate that H19 gene therapy prevents and reverses experimental, pressure-overload-induced heart failure,” said Dr. Thomas Thum, Professor at Hannover Medical School, CSO of Cardior and senior author of the study. “H19 acts as an anti-hypertrophic lncRNA and represents a promising therapeutic target to combat pathological cardiac remodeling.”

“H19 is a target of our proprietary RNA portfolio,” said Claudia Ulbrich, CEO of Cardior. "The impressive results of this study once again demonstrate the huge potential of RNA-based medicine for causal therapies of complex diseases. We are delighted to be among the pioneers of this emerging new paradigm.”

###
[1] Viereck J et al, Targeting muscle-enriched long non-coding RNA H19 reverses pathological cardiac hypertrophy”, European Heart Journal. doi:10.1093/eurheartj/ehaa519
After publication the paper can be found on the European Heart Journal website at:

https://academic.oup.com/eurheartj/article-lookup/doi/10.1093/eurheartj…

 

About Cardior
Cardior Pharmaceuticals is a privately held German biopharmaceutical company pioneering the development of curative and preventive heart failure therapeutics based on non-coding RNA (ncRNA). Cardior’s therapeutic approach is using distinctive ncRNA signatures driving the molecular reprogramming that causes maladaptive remodeling and heart failure. Drug candidates developed by Cardior represent first-in-class ncRNA therapeutics and diagnostics for patients with myocardial infarction and heart failure. Founded in 2016 based on the work of cardiologist Prof. Dr. Dr. Thomas Thum of Hannover Medical School, the Company has raised EUR 15 Mio. from international investors LSP Life Sciences Partners, BioMedPartners, Boehringer Ingelheim Venture Fund (BIVF), Bristol-Myers Squibb (BMS) and High-Tech Gründerfonds (HTGF).

 

Contact Cardior
Dr. Claudia Ulbrich / Barbara Gaertner-Rupprecht
Cardior Pharmaceuticals GmbH
Feodor-Lynen-Str. 15
30625 Hanover
Germany
Tel: +49 511 33 85 99 30

 

Media Inquiries
akampion
Dr. Ludger Wess / Ines-Regina Buth 
Managing Partners
info@akampion.com
Tel. +49 40 88 16 59 64
Tel. +49 30 23 63 27 68

close
Cardior Pharmaceuticals Demonstrates Reversal of Heart Failure with Lead Compound CDR132L
- Study by international research team published in Nature Communications
- Preclinical proof-of-concept of CDR132L established
- Inhibition of a regulatory microRNA restores cardiac function
read more

 

Hanover, Germany, January 31, 2020 - Cardior Pharmaceuticals GmbH, a clinical-stage biotech company focused on the development of noncoding RNA (ncRNA) therapeutics for patients with cardiovascular diseases, today announced a publication in Nature Communications demonstrating that its lead compound CDR132L is able to reverse heart failure in preclinical in vivo studies. The research was conducted by an international team of scientists from Austria, Germany, Hungary, and the U.K.

 

The compound is an antisense oligonucleotide inhibiting the microRNA 132 (miR132), a non-coding microRNA that regulates cardiac hypertrophy and autophagy in cardiomyocytes by targeting well-defined pathways. Expression of miR132 is increased in various pathological cardiac conditions in both animals and humans, and previous animal studies have shown that miR132 is both necessary and sufficient to drive the pathological growth of cardiomyocytes. miR132 is directly addressing the main causes of heart failure and therefore considerably differs from existing, mainly symptomatic therapies.

 

"miR132 is a regulatory master switch to control cardiac function and a promising therapeutic target in heart failure therapy," said Dr. Thomas Thum, Professor at Hannover Medical School, CSO of Cardior and corresponding author of the study. "In our publication, we demonstrate in various in vivo models that inhibition of miR132 is effective in reversing severe heart failure. We also show that elevation of miR132 levels in cardiomyocytes has negative effects on their contractile kinetics but can be normalized by antimiR-132 treatment."

 

First, the researchers demonstrated this effect in murine models overexpressing miR132. The team then investigated the compound in a larger model of heart failure closely mimicking the clinical situation in patients after myocardial infarction. These patients often develop heart failure despite successful cardiac catheterization. In the in vivo study, Cardior´s compound CDR132L effectively prevented maladaptive growth and remodeling and restored cardiac function in a dose-dependent manner. For a therapeutic effect, only two administrations of the compound were necessary.

 

"This important publication adds to our large body of evidence that CDR132L effectively halts and reverses heart failure by blocking a crucial regulatory RNA," said Claudia Ulbrich, CEO of Cardior. "If the currently ongoing clinical development continues to be successful, our approach will not only lead to an effective, causal treatment of heart failure, but may also pave the way to develop treatments of other complex diseases based on targeting non-coding regulatory RNAs."

 

###

The article is available for download here:   https://www.nature.com/articles/s41467-020-14349-2.pdf

 

About Cardior

Cardior Pharmaceuticals is a privately held German biopharmaceutical company pioneering the development of curative and preventive heart failure therapeutics based on non-coding RNA (ncRNA). Cardior’s therapeutic approach is using distinctive ncRNA signatures driving the molecular reprogramming that causes maladaptive remodeling and heart failure. Drug candidates developed by Cardior represent first-in-class ncRNA therapeutics and diagnostics for patients with myocardial infarction and heart failure. Founded in 2016 based on the work of cardiologist Prof. Dr. Dr. Thomas Thum of Hannover Medical School, the Company has raised EUR 15 Mio. from international investors LSP Life Sciences Partners, BioMedPartners, Boehringer Ingelheim Venture Fund (BIVF), Bristol-Myers Squibb (BMS) and High-Tech Gründerfonds (HTGF).

 

Contact Cardior

Dr. Claudia Ulbrich / Barbara Gaertner-Rupprecht

Cardior Pharmaceuticals GmbH
Feodor-Lynen-Str. 15
30625 Hanover

Germany

Tel: +49 511 33 85 99 30

 

Media Inquiries

akampion

Dr. Ludger Wess / Ines-Regina Buth

Managing Partners

info@akampion.com

Tel. +49 40 88 16 59 64

Tel. +49 30 23 63 27 68

close
Cardior at J.P. Morgan
Cardior will attend at J.P. Morgan in San Francisco, USA from 13th to 16th January 2020. read more

The annual J.P. Morgan Healthcare Conference (and partnering-meetings around) is the largest and most informative healthcare investment symposium in the industry, bringing together industry leaders, emerging fast-growth companies, innovative technology creators, and members of the investment community.

close
Cardior at BIO-Europe
Cardior team will attent at BIO-Europe in Hamburg, Germany from 11th to 13th November read more

BIO-Europe is held annually in different cities and is an international forum to promote business development between pharmaceutical, financial and biotechnology companies. The event is Europe's largest partnering conference serving the global biotech industry.

close
Cardior to present on 19th Annual Biotech in Europe Forum, 25th September, Basel (CH)
On Wednesday, Sep 25, 2019 Cardior´s CEO Dr. Claudia Ulbrich is going to give a company presentation at the upcoming #Sachs_BEF19 forum in Basel, Switzerland, (11:15-11:25 am CET in Room Lima; presention track B). read more

 

The 19th Annual Biotech in Europe Forum is recognised as the leading international stage for those interested in investing and partnering in the biotech and life science industry. The #Sachs_BEF19 forum will be held for the sixth time in Basel. 

close
Cardior to Present at Bio€quity Europe 2019
Cardior´s CEO Dr. Claudia Ulbrich is going to give a company presentation at the upcoming Bio€quity Europe 2019 in Barcelona, Spain, on Monday, May 20, 02:30-02:45pm CET in Room Rossini 2.

read more
CARDIOR part of 15 mn EU project CardioReGenix
The European Union has provided almost 15 million Euro to the research consortium CardioReGenix to support new gene therapy approaches for the treatment of heart disease. read more

Cardior is part of this research effort, which is being coordinated by Professor Marinee Chuah from the Free University of Brussels (VUB) and includes thirteen partners from six countries.

For further details, please visit:  

https://cordis.europa.eu/project/rcn/220263/factsheet/en

close
CARDIOR featured in 2018 year-end issue of BioWorld
We are proud to have been featured in the 2018 year-end issue of BioWorld. read more

The article highlights (quote) „the extraordinarily extensive preclinical dataset“ we have generated for our lead program, a microRNA (miRNA)-targeting oligonucleotide for the treatment of heart failure. The compound will enter a first-in-human Phase Ib trial in patients shortly.

For further details follow the link: http://www.bioworld.com/report/BWT01072019Cardior.pdf

close
CARDIOR CSO Prof Thum listed among the highly cited researchers 2018
Cardior Pharmaceuticals´ Chief Scientific Officer Prof. Dr. Dr. Thomas Thum has been listed among the highly cited researchers 2018. read more

The study performed by Clarivate Analytics selected world-class researchers for their exceptional research performance, demonstrated by production of multiple highly cited papers that rank in the top 1% by citations for field and year in Web of Science.

Link: https://hcr.clarivate.com/

 

close
CARDIOR presents at BioCapital Europe
Cardior Pharmaceuticals´ CEO Dr. Claudia Ulbrich to present at the upcoming BioCapital Europe in Amsterdam. read more

Time: 4:20pm CET

Room: Session Room 1 (St. Cecilia Chamber)

Location: Sofitel Legend Amsterdam The Grand, The Netherlands

Further information: https://www.biocapitaleurope.com

close
Cardior Receives EUR 1.01 Million Grant to Identify Novel Oligonucleotides for the Treatment of Chronic Heart Failure
Collaboration with Hannover Medical School (MHH)

Hanover, Germany, December 11, 2018 - Cardior Pharmaceuticals GmbH, a company focused on the development of noncoding RNA (ncRNA) therapeutics for patients with myocardial infarction and heart failure, today announced it has been granted EUR 1.01 million funding for a joint research project with the Institute of Molecular and Translational Therapeutic Strategies (IMTTS) at Hannover Medical School (MHH). read more

Goal of the project is the identification and preclinical development of therapeutic oligonucleotides for the treatment of heart diseases. Under the collaboration, Cardior expects to broaden its portfolio of drug candidates for the treatment of various heart failure indications.

The grant is provided by the state of Lower Saxony and the European Regional Development Fund (EFRE). The three-year collaboration will start in 2019.

“We aim to halt and reverse heart failure by blocking regulatory RNAs that play a crucial role in the onset and progression of the disease which comes in multiple forms,” said Prof. Dr. Thomas Thum, CSO of Cardior. “Our first product candidate CDR, a synthetic antisense-oligonucleotide, inhibits a molecular master-switch microRNA involved in the onset of heart failure after myocardial infarction. This approach can also be applied to other RNA targets and heart diseases. It is the goal of this collaboration to identify novel targets and therapeutic oligonucleotides so that we can expand our pipeline of drug candidates to combat heart diseases.”

Cardior’s collaboration partner, the Institute of Molecular and Translational Therapeutic Strategies (IMTTS, Hannover Medical School), is currently focusing on the identification of functional, long non-coding RNAs (lncRNAs), which play a crucial role in the processes of cardiac regeneration and ageing.

 

close
Cardior strengthens patent portfolio
Cardior strengthens patent portfolio of miRNAs for the diagnosis and therapy of heart and kidney diseases - Key patents acquired from Bayerische Patentallianz
read more

Hanover, Germany, November 1, 2018 - Cardior Pharmaceuticals GmbH, a company focused on the development of noncoding RNA (ncRNA) therapeutics for patients with myocardial infarction and heart failure, today announced it has acquired a portfolio of four microRNA (miRNA) patents from Bayerische Patentallianz GmbH (BayPAT). miRNAs are short pieces of ncRNA native to all human cells that act as regulators of gene expression. Cardior Pharmaceuticals has developed a novel class of ncRNA-based therapeutics modulating entire disease pathways to treat diseases with a high unmet medical need.

 

Among the inventors of the four acquired patents is Prof. Dr. med. Thomas Thum, co-founder and CSO of Cardior. The patents were filed while he was Research Group Leader at Julius-Maximilians-University, Wuerzburg (Germany). Financial terms were not disclosed. 

 

The acquired portfolio comprises three patents on the use of certain miRNAs for the diagnosis and treatment of heart diseases such as cardiac fibrosis and ischemia/ reperfusion injury and one patent covering a number of targets relevant for the diagnosis and treatment of ischemia/reperfusion injuries of the kidney. 

 

“We are delighted to expand our patent portfolio beyond heart diseases,” said Dr. Claudia Ulbrich, CEO of Cardior. “The transaction strengthens our position in cardiology and also enables us to move to further disease areas in the future.” 

 

She added that Cardior is preparing for the first clinical study of its lead candidate CDR, a synthetic antisense-oligonucleotide inhibitor of a molecular master-switch microRNA, which plays a crucial role in the development of heart failure. CDR aims to halt and reverse heart failure by acting on well-defined cellular pathways and is given by an easy route of administration. Cardior expects to initiate clinical studies in 2019. 

 

 

###

About Cardior

 

Cardior Pharmaceuticals is a privately held German biopharmaceutical company pioneering the development of curative and preventive heart failure therapeutics based on non-coding RNA (ncRNA). Cardior’s therapeutic approach is using distinctive ncRNA signatures driving the molecular reprogramming that causes maladaptive remodeling and heart failure. Drug candidates developed by Cardior represent first-in-class ncRNA therapeutics and diagnostics for patients with myocardial infarction and heart failure. Founded in 2016 based on the work of cardiologist Prof. Dr. Thomas Thum of Hanover Medical School, the Company has raised EUR 15 Mio. from international investors LSP Life Sciences Partners, BioMedPartners, Boehringer Ingelheim Venture Fund (BIVF), Bristol-Myers Squibb (BMS) and High-Tech Gründerfonds (HTGF).

 

Contact Cardior

Claudia Ulbrich / Barbara Gaertner-Rupprecht

Cardior Pharmaceuticals GmbH
Feodor-Lynen-Str.15
30625 Hanover

Germany

Tel: +49 511 33 85 99 30

 

Media Inquiries

akampion

Dr. Ludger Wess / Ines-Regina Buth

Managing Partners

info@akampion.com

Tel. +49 40 88 16 59 64

Tel. +49 30 23 63 27 68

close
Cardior has been selected as a participant in Euronext´s Techshare program
We are proud to announce that Cardior has been selected as a participant in Euronext´s Techshare program. read more

The capital markets training program for the first time includes non-listed German, Swiss, Italian and Spanish companies. Further information about Euronext Techshare can be found here:  https://tech.euronext.com/en/enternext-services/techshare

close
Cardior strengthens IP position for its lead candidate against heart failure
Cardior executed a licence agreement between Medical School Hannover (MHH) providing the company with exclusive and comprehensive rights to its lead candidate against heart failure. read more

The licence further consolidates Cardior’s strong IP position in the field and highlights recent progress. The oligonucleotide-based compound targets certain regulatory microRNAs which play a crucial role in pathological restructuring processes in the heart that occur in about 20% of patients following a heart attack. In vivo studies have shown that the candidate, by inhibiting the target microRNAs, not only stops the fatal restructuring of the heart, but actually reverses it. This could represent a breakthrough for millions of patients. Based on recent results, Cardior is now accelerating the preparation of clinical trials.

close
The Digital Female Leader Award
Successful women in the digital economy, hard to find? Here they are, the female founders and designers of companies, politics and society initiating, promoting and shaping digitization. read more

Claudia Ulbrich, Entrepreneur and CEO of Cardior Pharmaceuticals GmbH is one of them and we are delighted to announce her nomination as Digital Female Leader 2018 in the category science.
Take part in the online voting for the audience award here from August 1st-14th and vote for Claudia!
The Digital Female Leader Award #DFLA, an initiative of myself and Global Digital Women, outlines careers and motivations of successful women and role models from 11 categories. There will be three finalists in each category and the winner will be announced at the awards ceremony on December 1st, 2018.

 

Vote here: https://digital-female-leader.de

close
Cardior at HTGF Family-Day 2018
The Family Day is the biggest of High-Tech Gründerfond‘s networking events and 2018’s version will take place on May 29th and 30th at Kameha Grand Hotel Bonn, Germany. read more

At this exclusive annual two-day conference in Bonn, Dr. Claudia Ulbrich (CEO) and Prof. Dr. Dr. Thomas Thum (CSO) will take advantage of the excellent opportunities to meet representatives and investors of more than 300 international venture capital companies.

The conference offers next to Start Up-exhibition and face-to-face-meetings various workshops e.g. on pricing innovation, SME instruments and new ESOP options where business angels and partners of the HTGF network refer to their experiences and investment criteria.

close
Cardior will present latest developments at Bio€quity 2018
Dr. Claudia Ulbrich (CEO) will present Cardior’s latest developments in RNA-therapeutics for heart failure treatments at Bio€quity on May 15th, 2018. read more

During the 1:1 partnering event potential investors get the opportunity to learn more about the proprietary RNA technology revolutionizing heart failure treatment by targeting microRNAs.

Bio€quity Europe is the seminal industry event for financial dealmakers looking for investor-validated life science companies positioning themselves to attract capital, and for pharmaceutical licensing professionals to assess top prospects. Delegates from 24 nations attended Bio€quity Europe last year in Paris.

close
LATEST PRESS CONTRIBUTIONS:
Please find below a compilation of the latest press references:
(click "read more") read more
Cardior Represented in the German Biotech Startup Report 2017
Cardior is now represented in the German Biotech Startup Report 2017. read more

Cardior’s core competences, lead compound and market potential are displayed together with further key data and statistics, so potential investors and pharma-partners get easy access to our company profile.

Link: https://reports.labiotech.eu/german-biotech-startup-2017-cardior/

close
Dr. Wilfried Hauke
CARDIOR welcomes new CMO Dr. Wilfried Hauke
Dr. Wilfried Hauke joined CARDIOR as new Chief Medical Officer. read more

Wilfried is a physician by training specialized in pharmaceutical medicine. With more than 30 years of working in various fields of the pharmaceutical industry he gained outstanding experience in designing and leading clinical research studies, drug development and regulatory strategies.

Wilfried exhibits a wide range of competences in management and consulting starting his career at Hoechst AG, Frankfurt and Roussel UCLAF, Paris where he was involved in the clinical development of antibiotics and cardiovascular drugs. Using his unique combination of medical expertise and managerial experience he then served some international CROs as managing partner, CEO and CMO.

More recently Wilfried took over responsibility as CMO for Trophos, Marseille and was key in medical matters of their assets, which were successfully acquired by Roche in 2015. As CMO and board member of a stock listed company, Wilfried adapted the lead compound development strategy and initiated change management processes.  

Throughout his career he successfully set focus in risk-benefit-analysis and completed various due diligence projects supporting seller and purchaser perspective. He serves as Qualified Person for Pharmacovigilance for UK based mid-sized pharma companies and supports as Medical Advisor some orphan drug developments.

Wilfried built up a strong network of research specialists as well as high ranking industrial partners and investors. Additionally, he is longstanding member of the European Society of Cardiology, German Society of Internal Medicine, the German Society of Pharmaceutical Medicine, the Drug Information Association (DIA), Paul-Ehrlich Society of Chemotherapy (PEG) and the Faculty of Pharmaceutical Medicine at the Royal College of Physicians, London. Wilfried joined Cardior as CMO in early 2018.

close
Althusmann congratulates Cardior at DurchSTARTer 2017
On December 4th the finalists of the Start Up Award “DurchSTARTer 2017” competed for the title of this year’s most outstanding Start Up in Lower Saxony. After pitching in front of a mixed audience Cardior was awarded third place. read more

Dr. Bernd Althusmann, Minister of economic affairs, congratulated Dr. Claudia Ulbrich and Prof. Dr. Dr. Thum on Cardior’s outstanding progress in the field of non-coding RNA therapies.

close
Cardior welcomes new Chairman of the Board
In November 2017 Dr. Claus Kremoser was appointed as Chairman of Cardior’s Board of Directors. read more

Claus, Co-founder and CEO of Phenex Pharmaceuticals AG, is a highly skilled and longstanding expert in the Biotech- and Pharma-Industry sector. He brings along an extensive network of industrial partners and has a proven track record in deal making.

For more detailed information please refer to our board section.

close
Cardior winner of Biofit Start up Slam 2017
We proudly announce that Cardior was awarded first place at this year´s Biofit Start up Slam in Strasbourg. read more

Out of 70 competitors and 20 final contestants the steering committee chose Cardior together with Vaxinano as the most innovative and promising start-ups in 2017. In a high paced 6 minutes pitch Dr. Claudia Ulbrich (CEO) and Prof. Dr. Dr. Thomas Thum (CSO) convinced the experts with staggering news on Cardior‘s business strategy and investment opportunities.

close
Cardior elected for Start-up Slam at Biofit 2017
Next week Cardior will participate in the prestigious Start up Slam at Biofit 2017 in Strasbourg. A jury of experts elected Cardior as one of the most promising young Start up‘s to compete with 19 other entrepreneurs. read more

On November 28th, Dr. Claudia Ulbrich and Prof. Thomas Thum will pitch Cardior to a selection committee composed of high level representatives from international pharmaceutical and biotechnology industries, investors, technological transfer offices, biotechnology associations and public and private institutions. Based on their long lasting experience and knowledge, the panel of advisors will give feedback and offer advice to the selected applicants to support them developing their projects. Cardior will take part in Europe‘s leading partnering event to present its innovative non-coding RNA therapeutics and encounter future collaborators and partners.

close
Press Release: Cardior Pharmaceuticals raises €15 million and appoints CEO and CSO
Hannover, Germany, May 11th 2017 – Cardior Pharmaceuticals, today announced the completion of a €15 million Series A financing round led by LSP (Life Sciences Partners), Boehringer Ingelheim Venture Fund (BIVF), Bristol-Myers Squibb (BMS), BioMedPartners (with its new BioMedInvest III Fund) and High-Tech Gründerfonds (HTGF). read more

Cardior is pioneering its proprietary RNA technology to revolutionize predicting and treating heart failure. The molecular targets are non-coding RNAs linked to heart failure development that simultaneously control cardiac growth and calcium handling / contractility of cardiomyocytes.

The targeting of certain specific non-coding RNAs reverses maladaptive cardiac remodeling and restores normal cardiac function.  “We are very excited to be leading this financing” said Dr. Joachim Rothe, Managing Partner at LSP and a director of Cardior. “There has been a painful lack of scientific and clinical progress in the cardiovascular field for the past 15 years, and Cardior is well positioned to change this.” In conjunction with this financing, Cardior appointed Dr. Claudia Ulbrich as Chief Executive Officer.

Claudia brings with her two decades of operational management and corporate development experience in pharma and biotech including publicly traded companies. “It is a rare opportunity to develop cutting-edge science in the area of cardiovascular diseases with a high unmet medical need. I am delighted to join Cardior at this exciting development stage of the company and together with its motivated team, quickly put on the map a novel class of drugs and companion diagnostics with the potential to prevent and overcome heart failure” said Dr. Claudia Ulbrich. “The significant funding raised at this stage of development of the company will provide the resources for an ambitious development plan for our lead compound,” added Prof Thomas Thum, who is joining the management team as Chief Scientific Officer. With a translational approach and multiple established academic collaborations, Cardior is uniquely positioned to apply innovative first-in-class therapy for myocardial infarction and heart failure patients.

Cardior is currently developing non-coding RNA based assets and companion diagnostics. Additionally, Cardior has access to a great variety of discovery programs of undisclosed targets of Prof. Thum’s pipeline.  About Cardior Pharmaceuticals: Cardior Pharmaceuticals is a privately held German biotech company pioneering the next generation of non-coding RNA based therapeutics in heart failure. Prof Thomas Thum and his team have built a globally renowned expertise in the non-coding RNA field and demonstrated previously their ability to develop & partner innovative drug candidates. The Medical School Hannover (MHH) and the Institute of Molecular and Translational Therapeutic Strategies (IMTTS) offer a favorable bench-to-bedside environment to support Cardior as one of the world ́s leading centers in RNA biology.

The intellectual property was licensed from Medical School Hannover (MHH), the Max-Planck- Society (MPG) and from several world renowned French Institutes.

Cardior is the winner of the Startup Challenge at Deutsche Biotechnologietage 2017, the largest German biotech summit. Founded in 2016 by Prof Thum, Cardior was initially supported by VentureVilla Inkubator, hannoverimpuls and Ascenion.

 

Contact:

Dr. Claudia Ulbrich, CEO, Cardior Pharmaceuticals claudia.ulbrich@cardior.de

+49 511 37484051

Prof. Dr. Dr. Thomas Thum, CSO, Cardior Pharmaceuticals

+49 511 532 5272

thomas.thum@cardior.de

Image Credit: Karin Kaiser/MHH

close
Project leader Thomas Thum receives prestigious Outstanding Investigator Award
Project Leader Prof. Thomas Thum giving his Outstanding Investigator Award lecture at the 33rd Annual Meeting of the European Section of the International Society for Heart Research (ISHR) in Bordeaux. read more

Thomas was awarded the prestigious prize for his "research on non-coding RNAs in cardiovascular research and associated fields of research" that "provided new insight into the mode of action of various pathologies of the heart. He has developed major breakthroughs in both diagnostic and therapeutic approaches for cardiac diseases. Overall, his successful track record as a scientific investigator, translational scientist and Institute Director has established him as a leader in cardiovascular sciences."  Thomas joins Peter Carmeliet (2002), Issei Komuro (2003), Eric Olson (2005), Joseph Loscalzo (2006), Matthias Gautel (2009), Jeffery D. Molkentin (2010), Walter Koch (2011), Thomas Eschenhagen (2012), Deepak Srivastava (2013) and Asa Gustafsson (2014) in ISHR's Hall of Fame.

Further reading:  Press release    

 

close
PREV
NEXT

INVESTORS

PARTNERS

Career Opportunities

Looking
for a future
in medical
science?

JOBS @ CARDIOR 

Cardior Pharmaceuticals GmbH is a research-based biotechnology company based in Hanover. The company's goal is to develop RNA-based innovative diagnostics and therapeutics for patients with heart failure. The first reference product will be an oligonucleotide-based microRNA inhibitor. 

We have currently no job vacancies. You can send us a speculative application.

send your application here

Contact

Salutation